Hetero Biopharma launched Rilast (Rituximab) in Georgia – the first Biosimilar Rituximab in Georgia
Hetero Biopharma – the Biologics arm of Hetero Group has recently launched ‘Rilast’ (Rituximab) in Tbilisi, the capital city of Georgia on 28th Jan 2018. Rilast is the first Biosimilar Rituximab in Georgia.
Lead by Dr. Praveen Shetty - DGM, Global Clinical Strategy & Medico Marketing; Dr. Soso Davitashvili, Director Mermisi, Dr.DB Bhaskara Director Roerich Healthcare – Hetero’s business partners in Georgia – the product Rilast was launched in the presence of leading oncologists. The event served a great platform to launch Hetero Biopharma and its expertise in the area of Biosimilars. During this launch event, Dr. Praveen Shetty made a presentation on the Role of Rituximab in the management of NHL (Non-Hodgkins Lymphoma) and CLL (Chronic Lym phocytic Leukaemia) to the doctors.
Gallery
